Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

4.22

Today's Change

-0.33 (7.25%)

Day's Change

4.16 - 4.56

Trading Volume

2,369,342

Overview

Market Cap

1 Billion

Shares Outstanding

320 Million

Avg Volume

1,657,171

Avg Price (50 Days)

6.25

Avg Price (200 Days)

5.51

PE Ratio

-26.37

EPS

-0.16

Earnings Announcement

26-Feb-2025

Previous Close

4.55

Open

4.55

Day's Range

4.16 - 4.56

Year Range

1.8 - 8.975

Trading Volume

2,369,342

Price Change Highlight

1 Day Change

-7.25%

5 Day Change

-14.05%

1 Month Change

-25.70%

3 Month Change

-51.99%

6 Month Change

-8.26%

Ytd Change

100.00%

1 Year Change

122.11%

3 Year Change

460.68%

5 Year Change

181.33%

10 Year Change

181.33%

Max Change

181.33%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment